Romine v. Pfizer Inc.
This text of Romine v. Pfizer Inc. (Romine v. Pfizer Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 EASTERN DISTRICT OF CALIFORNIA 10 11 JACQUELINE R. ROMINE, Case No. 1:24-cv-01446-KES-CDB 12 Plaintiff, ORDER ON STIPULATION STAYING ACTION PENDING RULING ON 13 v. PETITION FOR MULTIDISTRICT LITIGATION 14 PFIZER INC., et al., (Doc. 14) 15 Defendants. 16 ORDER VACATING FEBRUARY 24, 2025 SCHEDULING CONFERENCE 17 (Doc. 2) 18 Background 19 Plaintiff Jacqueline R. Romine (“Plaintiff”) initiated this action with the filing of a 20 complaint on November 25, 2024, alleging claims for damages against Defendants Pfizer, Inc., 21 Pharacia & Upjohn Co. LLC, Pharmacia LLC, and Viatris Inc. (“Defendants”) arising from 22 Defendants’ wrongful conduct in connection with the development, design, testing, 23 manufacturing, labeling, packaging, promoting, advertising, marketing, distribution, and selling 24 of medroxyprogesterone acetate (“MPA”), also known as depot medroxyprogesterone acetate 25 (“DMPA”), and as a prescription drug under the trade name Depo-Provera® (“Depo-Provera”). 26 (Doc. 1 ¶ 1). Defendants’ respective responses to the complaint are due to be filed by late- 27 December 2024 or early-January 2025. (Docs. 9-13). 28 1 Stipulated Request to Stay 2 Pending before the Court is the parties’ stipulated request for order staying the action 3 pending a determination of a petition before the Judicial Panel on Multidistrict Litigation 4 (“JPML”). (Doc. 14). The parties represent that they are aware of at least 33 other actions 5 pending in United States District Courts in which the plaintiff is alleging personal injuries 6 relating to the use of Depo-Provera (“Depo-Provera cases”). (Id. at 3). The parties represent that 7 on November 26, 2024, the plaintiffs in several of the Depo-Provera cases petitioned the JPML 8 to centralize this and other Depo-Provera cases into a Multidistrict Litigation (“MDL”) (the 9 “Petition”). (Id.). The parties represent that the Petition is set for a hearing before the JPML on 10 January 30, 2025, and is expected to be decided upon in early February 2025. (Id.). 11 In light of the Petition, the parties have agreed to stay this action through at least 12 February 15, 2025, pending the JPML’s determination of the Petition. (Id.). The parties request 13 that the Court stay all pending deadlines and activities in this case. (Id.). The parties agree that 14 if the JPML has not ruled on the Petition by February 15, 2025, the parties shall file a joint status 15 update with the Court regarding the status of the Petition and whether an extension of the stay is 16 needed. (Id. at 4). The parties agree that if the JPML has denied the Petition to centralize the 17 instant action and other actions, Defendants shall have through and until 21 days after the JPML 18 rules on the anticipated Petition to respond to the complaint. (Id.). Thus, the parties jointly 19 request that this action be stayed until the JPML rules on the pending Petition or until February 20 15, 2025, whichever is sooner. (Id.). 21 “[T]he power to stay proceedings is incidental to the power inherent in every court to 22 control the disposition of the causes on its docket with economy of time and effort for itself, for 23 counsel, and for litigants.” Landis v. N. Am. Co., 299 U.S. 248, 254 (1936); Lockyer v. Mirant 24 Corp, 398 F.3d 1098, 1109 (9th Cir. 2005). Deciding whether to grant a stay pending the 25 outcome of other proceedings “calls for the exercise of judgment, which must weigh competing 26 interests and maintain an even balance.” United States v. Howen, No. 1:21-cv-00106-DAD- 27 SAB, 2022 WL 1004832, at *3 (E.D. Cal. Apr. 4, 2022) (quoting Landis, 299 U.S. at 254). “[I]f 28 there is even a fair possibility that the . . . stay will work damage to someone else, the party 1 seeking the stay must make out a clear case of hardship or inequity.” Lockyer, 398 F.3d at 1112; 2 United States v. Aerojet Rocketdyne Holdings, Inc., 381 F. Supp. 3d 1240, 1250 (E.D. Cal. May 3 8, 2019). 4 In considering whether to grant a stay, this Court must weigh several factors, including 5 “[1] the possible damage which may result from the granting of a stay, [2] the hardship or 6 inequity which a party may suffer in being required to go forward, and [3] the orderly course of 7 justice measured in terms of the simplifying or complicating of issues, proof, and questions of 8 law which could be expected to result from a stay.” CMAX, Inc. v. Hall, 300 F.2d 265, 268 (9th 9 Cir. 1962) (citing Landis, 299 U.S. at 254–55). In granting and lifting stays, a court must weigh 10 “the length of the stay against the strength of the justification given for it.” Yong v. I.N.S., 208 11 F.3d 1116, 1119 (9th Cir. 2000). “If a stay is especially long or its term is indefinite, [courts] 12 require a greater showing to justify it.” Id. A stay may be warranted in deference to ongoing, 13 parallel proceedings “regardless of whether the separate proceedings are ‘judicial, administrative, 14 or arbitral in character, and does not require that the issues in such proceedings are necessarily 15 controlling of the action before the court.’” Scottsdale Indemnity Co. v. Yamada, No. 1:18-cv- 16 00801-DAD-EPG, 2019 WL 7601833, at *3 (E.D. Cal. Jan. 10, 2019) (quoting Leyva v. Certified 17 Grocers of Cal., Ltd., 593 F.2d 857, 863-64 (9th Cir. 1979)). 18 Here, the interests of judicial economy and efficiency are served by staying this case until 19 the Petition pending before the JPML has been decided. Proceeding with the scheduling and 20 litigating of this action risks wasting judicial resources, as the Court will have to familiarize itself 21 with a case that may soon be centralized into a multidistrict litigation. 22 The Court does not find that the short stay anticipated will cause any hardship. The 23 parties stipulated to the request to stay and the case will not be delayed significantly given the 24 early stage of the litigation. The orderly course of justice weighs toward the grant of the 25 requested stay in order to avoid complicating of the issues or duplicative litigation should the 26 Petition be granted and the Depo-Provera cases, including the instant action, be centralized into a 27 Multidistrict Litigation. Furthermore, district courts within the Ninth Circuit routinely find good 28 cause to stay a case during the pendency of a petition before the JPML. See, e.g., Sprint 1 || Commc'ns Co. L.P. v. Pac. Bell Tel. Co., No. 2:14-cv-01257-MCE-CK, 2014 WL 7239474, at *2 2 ||(E.D. Cal. Dec. 16, 2014) (“The interests of judicial economy and efficiency are served by 3 || staying this case until the motion before the MDL Panel has been decided.”); see also A.H.M. v. 4 || Uber Techs., Inc., No. 23-cv-03482-JSC, 2023 WL 6199179 (N.D. Cal. Sept. 22, 2023); Hulsh v. 5 || Bayer Healthcare Pharms. Inc., No. 15-cv-04801-JST, 2016 WL 7168398 (N.D. Cal. Jan. 11, 6 || 2016). Therefore, because the Landis factors weigh toward granting of the stay, the Court finds 7 || that a stay of all proceedings is appropriate in this case. 8 For good cause shown in the parties’ stipulation, and the pending decision on the Petition 9 || before the JPML for which the parties agree Plaintiff would be subject to centralization into a 10 || Multidistrict Litigation, this action will be stayed pending the JPML’s determination of the 11 || Petition. 12 Conclusion and Order 13 Accordingly, in light of the parties’ representations and good cause appearing, IT IS 14 |] HEREBY ORDERED: 15 1.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
Romine v. Pfizer Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/romine-v-pfizer-inc-caed-2024.